Alternatives to dapagliflozin
3 same-class SPL records vs dapagliflozin - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Farxiga
How to read a high-report FAERS peer set
dapagliflozin ranks in the upper FAERS-volume third of the corpus (#140 of 524); 3 same-class peers are listed for field comparison only. Labeled indication field for dapagliflozin: This medicine can help adults with chronic kidney disease by reducing the risk of kidney problems, heart problems, and needing to go to the hospital for heart failure.
Top FAERS reaction fields for dapagliflozin total 24,632 reports across 10 reactions, set beside canagliflozin, empagliflozin, ertugliflozin. Counts are exposure-weighted submissions, not per-patient risk.
About dapagliflozin
Dapagliflozin (Farxiga) helps lower blood sugar in adults with type 2 diabetes. It also helps adults with heart failure or chronic kidney disease.
Used for: This medicine can help adults with chronic kidney disease by reducing the risk of kidney problems, heart problems, and needing to go to the hospital for heart failure. It can also help adults with heart failure by reducing the risk of heart problems and needing urgent care for heart failure. For adults with type 2 diabetes, it can help lower the risk of needing to go to the hospital for heart failure.
3 SGLT2 Inhibitor peers (wide set)
canagliflozin
RxInvokana
Invokana is used to help control blood sugar levels in adults with type 2 diabetes. It is used along with diet and exercise. Invokana can also lower the risk of major heart problems like heart attack and stroke in adults with both type 2 diabetes and heart disease. It can also reduce the risk of kidney failure, heart-related death, and hospitalization for heart failure in adults with type 2 diabetes and kidney problems.
empagliflozin
RxJardiance
ertugliflozin
RxSteglatro
dapagliflozin vs canagliflozin & empagliflozin · FAERS reaction fields
FAERS top-reaction field "Death" shows the widest count spread between dapagliflozin and canagliflozin, empagliflozin, ertugliflozin in this extract (5,608-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | dapagliflozin | canagliflozin | empagliflozin | ertugliflozin |
|---|---|---|---|---|
| Death | 7,017 | - | 1,409 | - |
| Fatigue | 2,250 | - | 2,590 | 23 |
| Nausea | 2,218 | 997 | 3,212 | 86 |
| Dizziness | 2,096 | 839 | 2,417 | 46 |
| Diarrhoea | 2,074 | 770 | 2,806 | 43 |
| Dyspnoea | 1,969 | - | 2,076 | - |
| Blood Glucose Increased | 1,861 | 1,227 | 3,043 | 46 |
| Weight Decreased | 1,827 | 1,340 | 2,749 | - |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
dapagliflozin FAERS volume vs class peers
FAERS volume band
dapagliflozin is FAERS corpus rank #140 of 524 (high volume tercile). Top-reaction field total: 24,632.
Frequently Asked Questions
Where does dapagliflozin sit in FAERS report volume vs SGLT2 Inhibitor peers? ▼
Registry note: FAERS counts are voluntary reports and do not establish causation or risk rates. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for dapagliflozin: see also the generic vs brand label guide when reading Farxiga SPL strings.
Read our methodology - how this data is sourced, computed, and verified.